Pharmaceutical companies under increased scrutiny.
Jagiellowicz
Jadzia
J
D003254:Consumer Advocacy; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects; D013375:Substance Withdrawal Syndrome; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors